Advertisement

Reasons for Nonadherence

  • Adrian PonaEmail author
  • Abigail Cline
  • Steven R. Feldman
Chapter
Part of the Updates in Clinical Dermatology book series (UCD)

Abstract

Patients’ failure to adhere to treatment regimens results in poor health outcomes and increased financial expenditure. Acknowledging common barriers to adherence can help providers anticipate how patients will incorporate treatment into their daily routine. Reasons for nonadherence may be patient-related, prescriber-related, and healthcare-related. Common reasons for nonadherence shared by the provider and patient include beliefs, perception of symptoms, cost, social support, education, forgetfulness, and psychiatric illnesses. Addressing common reasons for nonadherence can improve adherence and overall treatment outcome.

Keywords

Nonadherence Healthcare provider Patient Reasons Barriers 

Notes

Conflicts of Interest

Dr. Steven Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.

Dr. Adrian Pona and Dr. Abigail Cline have no conflicts to disclose.

References

  1. 1.
    Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.CrossRefPubMedGoogle Scholar
  3. 3.
    Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Feldman SR, Vrijens B, Gieler U, Piaserico S, Puig L, van de Kerkhof P. Treatment adherence intervention studies in dermatology and guidance on how to support adherence. Am J Clin Dermatol. 2017;18(2):253–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Nafradi L, Galimberti E, Nakamoto K, Schulz PJ. Intentional and unintentional medication non-adherence in hypertension: the role of health literacy, empowerment and medication beliefs. J Public Health Res. 2016;5(3):762.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud. 2007;44(8):1468–77.CrossRefPubMedGoogle Scholar
  7. 7.
    Sabate E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.Google Scholar
  8. 8.
    Horne R, Weinman J, Barber N, Elliot R, Morgan M. Adherence and compliance in medicine taking. Report for the National Coordinating Centre for NHS Service Delivery and Organization R and D (NCCSDO). 2005 [Available from: http://www.netscc.ac.uk/hsdr/files/project/SDO_FR_08-1412-076_V01.pdf.
  9. 9.
    Arts DL, Voncken AG, Medlock S, Abu-Hanna A, van Weert HC. Reasons for intentional guideline non-adherence: a systematic review. Int J Med Inform. 2016;89:55–62.CrossRefPubMedGoogle Scholar
  10. 10.
    DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45(6):521–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Devine F, Edwards T, Feldman SR. Barriers to treatment: describing them from a different perspective. Patient Prefer Adherence. 2018;12:129–33.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013;30(1):29–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Wade R, Paton F, Woolacott N. Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. J Adv Nurs. 2017;73(2):336–48.CrossRefPubMedGoogle Scholar
  14. 14.
    Patel NU, D'Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol. 2017;18(3):323–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Ellis RM, Koch LH, McGuire E, Williams JV. Potential barriers to adherence in pediatric dermatology. Pediatr Dermatol. 2011;28(3):242–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Gokdemir G, Ari S, Koslu A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol. 2008;22(3):330–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Lewis DJ, Feldman SR. Practical ways to improve patient adherence. Columbia, SC: CreateSpace Independent Publishing Platform. 2017.Google Scholar
  18. 18.
    Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Vitalis D. Factors affecting antiretroviral therapy adherence among HIV-positive pregnant and postpartum women: an adapted systematic review. Int J STD AIDS. 2013;24(6):427–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Storm A, Benfeldt E, Andersen SE, Andersen J. Basic drug information given by physicians is deficient, and patients' knowledge low. J Dermatolog Treat. 2009;20(4):190–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Holtzman CW, Shea JA, Glanz K, Jacobs LM, Gross R, Hines J, et al. Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen’s Behavioral Model. AIDS Care. 2015;27(7):817–28.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Brundisini F, Vanstone M, Hulan D, DeJean D, Giacomini M. Type 2 diabetes patients’ and providers’ differing perspectives on medication nonadherence: a qualitative meta-synthesis. BMC Health Serv Res. 2015;15:516.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    O’Rourke G, O’Brien JJ. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure. 2017;45:160–8.CrossRefGoogle Scholar
  25. 25.
    Meiners M, Tavares NUL, Guimaraes LSP, Bertoldi AD, Pizzol T, Luiza VL, et al. Access and adherence to medication among people with diabetes in Brazil: evidences from PNAUM. Rev Bras Epidemiol. 2017;20(3):445–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Shirneshan E, Kyrychenko P, Matlin OS, Avila JP, Brennan TA, Shrank WH. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence. J Clin Pharm Ther. 2016;41(1):64–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee M, Salloum RG. Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors. J Cancer Surviv. 2016;10(3):534–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Medication Adherence Tech: a dynamic and crowded market, but where are all the winners in the space? (Part 1 of 2) 2017. Available from: https://www.mobihealthnews.com/content/medication-adherence-tech-dynamic-and-crowded-market-where-are-winners-space-part-1-2.
  29. 29.
    Shafer PO, Buchhalter J. Patient education: identifying risks and self-management approaches for adherence and sudden unexpected death in epilepsy. Neurol Clin. 2016;34(2):443–56.. ixCrossRefPubMedGoogle Scholar
  30. 30.
    McKenzie K, Forsyth K, O'Hare A, McClure I, Rutherford M, Murray A, et al. The relationship between waiting times and ‘adherence’ to the Scottish Intercollegiate Guidelines Network 98 guideline in autism spectrum disorder diagnostic services in Scotland. Autism. 2016;20(4):395–401.CrossRefPubMedGoogle Scholar
  31. 31.
    Sears C, Andersson Z, Cann M. Referral systems to integrate health and economic strengthening services for people with HIV: a qualitative assessment in Malawi. Glob Health Sci Pract. 2016;4(4):610–25.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kehler DS, Kent D, Beaulac J, Strachan L, Wangasekara N, Chapman S, et al. Examining patient outcome quality indicators based on wait time from referral to entry into cardiac rehabilitation: a PILOT OBSERVATIONAL STUDY. J Cardiopulm Rehabil Prev. 2017;37(4):250–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30(5):512–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Manne JM, Snively CS, Ramsey JM, Salgado MO, Barnighausen T, Reich MR. Barriers to treatment access for Chagas disease in Mexico. PLoS Negl Trop Dis. 2013;7(10):e2488.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Baker DW. The meaning and the measure of health literacy. J Gen Intern Med. 2006;21(8):878–83.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wolf MS, Davis TC, Osborn CY, Skripkauskas S, Bennett CL, Makoul G. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns. 2007;65(2):253–60.CrossRefPubMedGoogle Scholar
  37. 37.
    In: Nielsen-Bohlman L, Panzer AM, Kindig DA, editors. Health literacy: a prescription to end confusion. Washington DC: 2004 by the National Academy of Sciences; 2004.Google Scholar
  38. 38.
    Kutner M, Greenberg E, Jin Y, Paulsen C. The health literacy of America’s adults: results from the 2003 National Assessment of Adult Literacy (NCES 2006-483). Washington, DC: U.S. Department of Education: National Center for Education Statistics; 2006.Google Scholar
  39. 39.
    Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. Patient Educ Couns. 2016;99(7):1079–86.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. Am J Med Sci. 2016;351(4):387–99.CrossRefPubMedGoogle Scholar
  41. 41.
    Hayward KL, Martin JH, Cottrell WN, Karmakar A, Horsfall LU, Patel PJ, et al. Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. Trials. 2017;18(1):339.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kobak KA, Taylor L, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry. 2002;63(8):727–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.CrossRefPubMedGoogle Scholar
  44. 44.
    Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Galvan FH, Bogart LM, Wagner GJ, Klein DJ, Chen YT. Conceptualisations of masculinity and self-reported medication adherence among HIV-positive Latino men in Los Angeles, California, USA. Cult Health Sex. 2014;16(6):697–709.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Winters A, Esse T, Bhansali A, Serna O, Mhatre S, Sansgiry S. Physician perception of patient medication adherence in a cohort of medicare advantage plans in Texas. J Manag Care Spec Pharm. 2016;22(3):305–12.PubMedGoogle Scholar
  48. 48.
    Lapane KL, Dube CE, Schneider KL, Quilliam BJ. Misperceptions of patients vs providers regarding medication-related communication issues. Am J Manag Care. 2007;13(11):613–8.PubMedGoogle Scholar
  49. 49.
    Linder LA, Wu YP, Macpherson CF, Fowler B, Wilson A, Jo Y, et al. Oral medication adherence among adolescents and young adults with cancer before and following use of a smartphone-based medication reminder app. J Adolesc Young Adult Oncol. 2018;8(2):122–30.CrossRefPubMedGoogle Scholar
  50. 50.
    Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Simons LE, McCormick ML, Mee LL, Blount RL. Parent and patient perspectives on barriers to medication adherence in adolescent transplant recipients. Pediatr Transplant. 2009;13(3):338–47.CrossRefPubMedGoogle Scholar
  52. 52.
    Koster ES, Philbert D, de Vries TW, van Dijk L, Bouvy ML. “I just forget to take it”: asthma self-management needs and preferences in adolescents. J Asthma. 2015;52(8):831–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Muluneh B, Deal A, Alexander MD, Keisler MD, Markey JM, Neal JM, et al. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. J Oncol Pharm Pract. 2018;24(2):98–109.CrossRefPubMedGoogle Scholar
  54. 54.
    Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology. 2008;217(4):309–14.CrossRefPubMedGoogle Scholar
  55. 55.
    Goren A, Carter C, Lee S. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis. J Dermatolog Treat. 2016;27(1):43–50.CrossRefPubMedGoogle Scholar
  56. 56.
    Pena-Robichaux V, Kvedar JC, Watson AJ. Text messages as a reminder aid and educational tool in adults and adolescents with atopic dermatitis: a pilot study. Dermatol Res Pract. 2010;2010:1–6.CrossRefGoogle Scholar
  57. 57.
    Tarn DM, Flocke SA. New prescriptions: how well do patients remember important information? Fam Med. 2011;43(4):254–9.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Jansen J, Butow PN, van Weert JC, van Dulmen S, Devine RJ, Heeren TJ, et al. Does age really matter? Recall of information presented to newly referred patients with cancer. J Clin Oncol. 2008;26(33):5450–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Rork JF, Sheehan WJ, Gaffin JM, Timmons KG, Sidbury R, Schneider LC, et al. Parental response to written eczema action plans in children with eczema. Arch Dermatol. 2012;148(3):391–2.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Bloomberg J. Digital transformation moves pharma ‘Beyond the Pill’ 2014. Available from: https://www.forbes.com/sites/jasonbloomberg/2014/08/15/digital-transformation-moves-pharma-beyond-the-pill/#774a89ab1c58.
  61. 61.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874–88.PubMedGoogle Scholar
  63. 63.
    Kulkarni AS, Balkrishnan R, Camacho FT, Anderson RT, Feldman SR. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol. 2004;3(6):661–6.PubMedGoogle Scholar
  64. 64.
    Li Y, Zhou H, Cai B, Kahler KH, Tian H, Gabriel S, et al. Group-based trajectory modeling to assess adherence to biologics among patients with psoriasis. Clinicoecon Outcomes Res. 2014;6:197–208.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):7–16.CrossRefPubMedGoogle Scholar
  66. 66.
    Silverberg JI. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol. 2017;35(4):360–6.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78(1):156–66.CrossRefPubMedGoogle Scholar
  68. 68.
    Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18(5):613–20.CrossRefPubMedGoogle Scholar
  69. 69.
    Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47(3):259–69.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006–2007. JAMA. 2009;302(16):1755–6.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Williams J, Steers WN, Ettner SL, Mangione CM, Duru OK. Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes. Med Care. 2013;51(2):193–8.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Blanchard J, Madden JM, Ross-Degnan D, Gresenz CR, Soumerai SB. The relationship between emergency department use and cost-related medication nonadherence among Medicare beneficiaries. Ann Emerg Med. 2013;62(5):475–85.CrossRefPubMedGoogle Scholar
  73. 73.
    Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013;40(2):137–43.CrossRefPubMedGoogle Scholar
  74. 74.
    Musich S, Cheng Y, Wang SS, Hommer CE, Hawkins K, Yeh CS. Pharmaceutical cost-saving strategies and their association with medication adherence in a Medicare Supplement Population. J Gen Intern Med. 2015;30(8):1208–14.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Zhang Y, Baik SH. Race/ethnicity, disability, and medication adherence among medicare beneficiaries with heart failure. J Gen Intern Med. 2014;29(4):602–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol. 2006;175(3 Pt 1):1067–71; discussion 71–2.CrossRefPubMedGoogle Scholar
  77. 77.
    Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54–65.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730–40.PubMedGoogle Scholar
  80. 80.
    Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008;1:CD007017.Google Scholar
  81. 81.
    Slota C, Davis SA, Blalock SJ, Carpenter DM, Muir KW, Robin AL, et al. Patient-physician communication on medication cost during Glaucoma visits. Optom Vis Sci. 2017;94(12):1095–101.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol. 2006;7(4):231–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263–71.CrossRefPubMedGoogle Scholar
  84. 84.
    Shokeen D, O’Neill JL, Taheri A, Feldman SR. Are topical keratolytic agents needed in the treatment of scalp psoriasis? Dermatol Online J. 2014;20(3).Google Scholar
  85. 85.
    Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59(6):1009–16.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Adrian Pona
    • 1
    Email author
  • Abigail Cline
    • 1
  • Steven R. Feldman
    • 2
  1. 1.Department of DermatologyWake Forest School of MedicineWinston-SalemUSA
  2. 2.Departments of Dermatology, Pathology and Social Sciences & Health PolicyWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations